[Cited FineTest ELISA Kit] Current Research on Lipid Nanoparticles COVID Vaccine

FineTest ELISA kit contributes to the research on lipid nanoparticles COVID vaccine. The immunoassay is designed to measure 2019 nCoV(S)IgA concentration in BALF and serum.

Publication Details
Article Title: Virus-like structures for combination antigen protein mRNA vaccination
Journal Title: Nature Nanotechnology
DOI: 10.1038/s41565-024-01679-1
IF: 38.3
PMID: 38802667

Abstract: Improved vaccination requires better delivery of antigens and activation of the natural immune response. Here we report a lipid nanoparticle system with the capacity to carry antigens, including mRNA and proteins, which is formed into a virus-like structure by surface decoration with spike proteins, demonstrating application against SARS-CoV-2 variants. The strategy uses S1 protein from Omicron BA.1 on the surface to deliver mRNA of S1 protein from XBB.1. The virus-like particle enables specific augmentation of mRNAs expressed in human respiratory epithelial cells and macrophages via the interaction the surface S1 protein with ACE2 or DC-SIGN receptors. Activation of macrophages and dendritic cells is demonstrated by the same receptor binding. The combination of protein and mRNA increases the antibody response in BALB/c mice compared with mRNA and protein vaccines alone. Our exploration of the mechanism of this robust immunity suggests it might involve cross-presentation to diverse subsets of dendritic cells ranging from activated innate immune signals to adaptive immune signals.

Keywords: SARS-CoV-2 variants, COVID-19, Lipid Nanoparticles, Vaccination, Biomaterials, Nanobiotechnology

Immunoassay

Validated Image

Figure Source: Nat Nanotechnol. 2024 May 27. doi: 10.1038/s41565-024-01679-1.